Health Care & Life Sciences » Pharmaceuticals | Biostar Pharmaceuticals Inc.

Biostar Pharmaceuticals Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2012
2013
2014
2015
2016
Cash & Short Term Investments
1,759.10
80.10
1,685.20
38.90
173.40
Total Accounts Receivable
35,722.10
31,639.40
36,801.90
15,891.20
6,854.20
Inventories
847.10
1,484.70
674.00
234.70
166.60
Other Current Assets
3,645.80
2,781.30
4,472.00
2.60
171.00
Total Current Assets
41,974.10
35,985.50
43,633.00
16,167.30
7,365.10
Net Property, Plant & Equipment
6,980.50
7,728.70
8,483.10
6,810.90
6,755.10
Total Investments and Advances
-
-
8,795.20
16,100.00
19,079.00
Intangible Assets
9,136.40
17,134.50
13,270.30
6,878.80
5,607.10
Other Assets
8,718.30
3,926.60
-
-
1,180.70
Total Assets
70,475.30
67,564.40
81,247.20
51,363.60
42,502.40
ST Debt & Current Portion LT Debt
6,340.60
-
3,094.60
2,773.20
2,325.60
Accounts Payable
5,732.30
4,447.30
5,001.10
4,153.40
2,842.10
Income Tax Payable
629.70
344.20
432.90
112.60
-
Other Current Liabilities
0.00
0.00
383.30
59.20
455.50
Total Current Liabilities
12,702.60
4,791.50
8,911.90
7,098.40
5,623.30
Deferred Taxes
3,666.00
2,789.20
7,065.50
5,406.60
2,515.30
Total Liabilities
12,702.60
4,791.50
8,911.90
7,098.40
5,623.30
Common Equity (Total)
57,772.70
62,772.90
72,335.40
44,265.10
36,879.20
Total Shareholders' Equity
57,772.70
62,772.90
72,335.40
44,265.10
36,879.20
Total Equity
57,772.70
62,772.90
72,335.40
44,265.10
36,879.20
Liabilities & Shareholders' Equity
70,475.30
67,564.40
81,247.20
51,363.60
42,502.40

About Biostar Pharmaceuticals

View Profile
Address
No. 588 Shiji Xi Avenue
Xianyang Shaanxi 712046
China
Employees -
Website http://www.biostarpharmaceuticals.com
Updated 07/08/2019
BioStar Pharmaceuticals, Inc. engages in the development, manufacture, and marketing of pharmaceutical and health supplement products for a variety of diseases and conditions. It's products include Xin Ao Xing Oleanolic Acid Capsule, an over-the-counter medicine for chronic hepatitis B, a disease affecting the Chinese population. The company was founded on March 27, 2007 and is headquartered in Xianyang, China.